Article -> Article Details

Market Overview

The Vietnam cancer biomarkers market reached a size of USD 138.49 Million in 2025 and is projected to grow at a CAGR of 10.62% from 2026 to 2034. By 2034, the market is expected to reach USD 343.44 Million. Growth is driven by rising cancer prevalence, advancements in precision medicine, increasing healthcare spending, government investment in digital health and diagnostic technologies, and a shift toward personalized treatment and biomarker diagnostics.

Study Assumption Years

• Base Year: 2025
• Historical Year/Period: 2020-2025
• Forecast Year/Period: 2026-2034

Vietnam Cancer Biomarkers Market Key Takeaways

• Current Market Size: USD 138.49 Million (2025)
• CAGR: 10.62%
• Forecast Period: 2026-2034
• The market is propelled by increasing cancer incidence fueled by population aging, urbanization, and lifestyle changes.
• Government initiatives focus on enhancing cancer care via investment in high-tech labs, oncology units, and cancer registries.
• Precision medicine adoption is expanding, emphasizing biomarker-guided therapy especially for breast, lung, and colorectal cancers.
• Digital health integration and public-private partnerships accelerate biomarker technology adoption and improve diagnostic access.
• Research collaborations between local and international institutions enhance knowledge transfer and advance biomarker utilization.

Sample Request Link: https://www.imarcgroup.com/vietnam-cancer-biomarkers-market/requestsample

Market Growth Factors

Growth in the Vietnam cancer biomarkers market is due to the growing burden of breast cancer, lung cancer, prostate cancer and others, attributed to the aging population, urbanization, and changing lifestyles. Furthermore, increasing availability of diagnostic centers and their capacity to perform early detection and precision medicine will drive market growth. The main government investments were made into high-tech laboratory infrastructure, specialized oncological departments, and national cancer registries. Medical centers also adopted biomarker testing protocols and increased sensitivity, as well as improving treatment protocols in specialized tumor boards. Joint research between the Vietnamese and foreign medical institutions strengthens the transfer of knowledge and technology, and leads to an increased need for biomarker technologies, from protein-based assays to genomic profiling.

Precision medicine is the main growth driver in the market. Biomarker guided treatment aimed at the exact biology of the patient's tumor has become the main driving force, and biomarker testing is routinely used to tailor therapy to the patient to improve response and safety and reduce costs. Routine companion diagnostic testing is now standard of care in breast, lung, and colon cancer. At academic centers, molecular tumor boards review biomarker data. Investment in bioinformatics and laboratory and clinical training for investigators at local institutions allows each center to build its own expertise in interpreting molecular data, which expands the role of biomarker-guided precision oncology across different cancer types.

High infrastructure spending on diagnosis and IT/ digital health in Vietnam is driving the market. The government in Vietnam is providing financial support to modernize cancer care, diagnostic labs, and technologies to develop advanced infrastructure. Digital health tools can improve biomarker testing workflows through electronic health records, laboratory information systems, and telemedicine platforms. Public-private partnerships and policies within the healthcare system have supported the adoption and regulatory approval of biomarker tests. Increased coverage by national health insurance broadens access to biomarker diagnostics. Medical education, research and international partnerships can foster local biomarker diagnostic expertise and allow technology transfer and best practice development between Vietnamese and international institutions.

Market Segmentation

• Profiling Technology:
• Omic Technologies: Advanced molecular profiling platforms critical for precision diagnostics.
• Imaging Technologies: Techniques facilitating biomarker detection through visualization.
• Immunoassays: Protein-based assays used in traditional biomarker detection.
• Cytogenetics: Analysis of chromosomal abnormalities for cancer diagnostics.
• Biomolecule:
• Genetic Biomarkers: DNA/RNA-based markers used in molecular cancer diagnostics.
• Protein Biomarkers: Protein expressions utilized for diagnostic and prognostic purposes.
• Glyco-Biomarkers: Carbohydrate-related markers involved in cancer detection.
• Cancer Type:
• Breast Cancer: A primary target for biomarker-driven therapies.
• Lung Cancer: Major focus for personalized diagnostic and treatment approaches.
• Colorectal Cancer: Tumor profiling supports treatment selection.
• Prostate Cancer: Biomarkers assist in diagnosis and progression monitoring.
• Stomach Cancer: Biomarker usage expands detection and treatment efficiency.
• Others: Additional cancer types included within the market scope.
• Application:
• Diagnostics: Identification of cancer presence via biomarkers.
• Prognostics: Predictive applications for disease outcome.
• Risk Assessment: Evaluation of cancer development risk.
• Drug Discovery and Development: Biomarkers supporting therapeutic research.
• Others: Additional applications related to cancer biomarker use.
• End User:
• Hospitals: Primary sites for biomarker testing and treatment application.
• Academic and Research Institutions: Entities conducting biomarker research and clinical validation.
• Ambulatory Surgical Centers: Facilities utilizing biomarker diagnostics.
• Diagnostic Laboratories: Specialized labs for biomarker analysis.
• Others: Other end users involved in biomarker applications.

Regional Insights

The Vietnam cancer biomarkers market is analyzed across Northern Vietnam, Central Vietnam, and Southern Vietnam. Specific detailed statistics such as market share or CAGR by region are not provided in the source. The segmented analysis covers all major regional markets, reflecting national healthcare infrastructure development and cancer care investment across these areas.

Competitive Landscape

The competitive landscape of the industry has also been examined along with the profiles of the key players.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302